| Farhaan Hafeez, MD | |
|
1600 St Lukes Blvd Ste 100, Easton, PA 18045-5671 | |
| (484) 503-7546 | |
| Not Available |
| Full Name | Farhaan Hafeez |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 1600 St Lukes Blvd Ste 100, Easton, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720491988 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | MD467489 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| St Luke's Warren Hospital | Phillipsburg, NJ | Hospital |
| St Luke's Hospital - Monroe Campus | Stroudsburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
| Gslpg, Inc | 7810226875 | 227 |
| St Lukes Warren Physician Group Pc | 9739093675 | 314 |
News Archive
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumor cells.
› Verified 7 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumor cells.
› Verified 7 days ago
| Entity Name | Star Community Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033686159 PECOS PAC ID: 7618215237 Enrollment ID: O20190206002009 |
News Archive
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumor cells.
› Verified 7 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumor cells.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Farhaan Hafeez, MD 801 Ostrum St, Bethlehem, PA 18015-1000 Ph: (484) 526-4000 | Farhaan Hafeez, MD 1600 St Lukes Blvd Ste 100, Easton, PA 18045-5671 Ph: (484) 503-7546 |
News Archive
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumor cells.
› Verified 7 days ago
Carla V Shiller, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12 Stonecroft Dr, Easton, PA 18045 Phone: 908-391-2548 | |
Aspen Reilly Trautz, Dermatology Medicare: Medicare Enrolled Practice Location: 1700 St Lukes Blvd Ofc, Easton, PA 18045 Phone: 484-526-1000 | |
Mia Woloszyn, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1872 St Lukes Blvd, Easton, PA 18045 Phone: 484-503-4007 | |
Nadia Yasmin Abidi, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1600 St Lukes Blvd, Easton, PA 18045 Phone: 484-503-7546 |